Global law firm White & Case LLP has advised OncoDNA, a leading international player in precision oncology medicine, on its friendly takeover bid for Euronext Growth-listed IntegraGen.
The transaction was announced in July 2020 and the tender offer declared compliant by the Autorité des Marchés Financiers (AMF) (The French financial markets authority) on September 15, 2020. The transaction was successfully concluded on November 16, 2020, following the reopening period and the publication by the AMF of the final results.
OncoDNA now holds a total of 4,270,896 shares, representing 63.71 percent of the share capital and theoretical voting rights and 64.26 percent of effective voting rights, and becomes Integragen’s majority shareholder.
The transaction brings together OncoDNA’s expertise in precision oncology medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of both companies offers a complete solution that combines oncology laboratory testing and software solutions, which will benefit the treatment of patients with advanced cancer.
The White & Case team in Paris which advised on the transaction was led by partners Alexis Hojabr and Franck De Vita and included partners Alexandre Jaurett, Jean-Luc Champy and Clara Hainsdorf, counsel Orion Berg and associates Agathe Delalande, Alexandre Balat, Margaux de Lembeye, Dany Luu, Camille Grimaldi, Camille Fouqué and Laura Tuszynski.
For more information, please speak to your local media contact.